Posted by Michael Wonder on 15 Mar 2018
Product withdrawn after overseas reports of inflammatory brain disorders
15 March 2018 - Consumers and health professionals are advised that Biogen Australia, in consultation with the TGA, will withdraw Zinbryta (daclizumab) from the Australian market following cases of serious inflammatory brain disorders in Europe.
Zinbryta is used for the treatment of relapsing forms of multiple sclerosis to delay the progression of physical disability and to reduce the frequency of relapse. It can only be prescribed to patients who are being treated by a neurologist.
The TGA has not received any reports of inflammatory brain disorders occurring in Australian patients who have been prescribed Zinbryta.
